COSCIENS Biopharma【CSCI】銘柄情報

COSCIENS Biopharma Inc (CSCI) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

2.72

( - )

買値

2.53

売値

2.59

出来高

0.00 日の範囲 0.00

0.00 52 週間の範囲 0.00

前日終値

2.72

始値

時刻

最終取引時間

平均取引量 (3 か月)

財務取引量

VWAP

COSCIENS Announces Exclusive Distribution Agreement with Wuzhou Drug International for Macrilen® in Hainan-Guangdong-Hong Kong-Macao Greater Bay Area and Singapore

TORONTO, ONTARIO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF...

COSCIENS Biopharma Inc. Announces Leadership Change

TORONTO, ONTARIO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF...

COSCIENS Biopharma Inc. Reports Third Quarter 2025 Financial Results and Provides Strategic Initiatives Update

COSCIENS voluntarily delists from Nasdaq, while retaining the Company’s listing on the TSX COSCIENS...

Form 25 - Notification of the removal from listing and registration of matured, redeemed or retired securities

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update

COSCIENS Board of Directors approves a plan to voluntarily delist from Nasdaq, while retaining the Company’s...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

CSCI - Frequently Asked Questions (FAQ)

What is the current COSCIENS Biopharma Inc share price?

The current share price of COSCIENS Biopharma Inc is US$ 2.72

What is the 1 year trading range for COSCIENS Biopharma Inc share price?

COSCIENS Biopharma Inc has traded in the range of US$ 0.00 to US$ 0.00 during the past year

jimr1717 4分前

Has updated timeline 39Z-4 been updated?

ELTP

researcher59 6分前

SPCX - retail shares are not restricted, but Fidelity may limit access to futures IPOs for those who flip their shares in under 15 days.

The IPO may be oversubscribed, so if you ask for 50 shares you might only get 25.

https://www.businessinsider.com/spacex-ipo-fidelity

SPCX

JimmyRich 6分前

🙏🏼🙏🏼🙏🏼 my friend

UEEC

bbotcs 6分前

INTU is near its 52-week low. If the perception among hedge fund managers and other institutional investors is that AI is going to hurt Intuit, it is going to stay down, imo.
The company needs a strong AI strategy.
Also, the dividend yield is not good. IMO, investors are not getting

INTU

Doc logic 8分前

brazen22,

That is certainly one way of thinking. I personally don’t have a problem with that but there still remains the bigger picture to consider. In my view “the process” and the framework it is built on is the problem creating this kind of dilemma that all parties are required t

NWBO

walterc 9分前

th6565. what is your nationality?

jimr1717 11分前

“Although Wertheim & Co. no longer exists as an independent entity” ❌

Only Fools are Fooled

https://wertheimandcompany.com/transactions/

GTCH

Top Penny 12分前

Why not? Because you are short and nobody can make coin except you? Try again because you lose here pal!!!

PSRU

Top Penny 13分前

Within in the next 30 days IMO, soon trips are history for good!!!

PSRU

Top Penny 13分前

.007 minimum

PSRU

Lve 15分前

What do you think the price will go to?

PSRU

joe botts 15分前

Nope

PSRU

prowler3701 16分前

Are we still in the quiet period?? LOL!!

Are we still the game changing, jaw dropping, next Lionsgate, tentpole movie, myflix tail that wags the dog, unbelievable movie distributor lol.

17 years of failure buffoon boy CEO.

Jack Wagon CEO!!

HHSE

richme 16分前

Guess there is the problem of numbers in the clientele realm??

TWOH

flipper44 16分前

It’s been half a year since the ASM. It’s been over two and a half years since the MAA was submitted. It’s been two decades since the phase iii trial appeared on clinicaltrials.gov.

It’s great they are all around the world advocating for cancer vaccines, but we need an update. We

NWBO

Lve 16分前

Hopefully soon

PSRU

DewDiligence 17分前

Berobenatide—dosed monthly—appears_competitive_with_weekly Zepbound/Wegovy in efficacy/tolerability—see slide 7 at the link in #msg-177679183.

PFE

US Market News 17分前

Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complicationsJune 6, 2026 2:30 PM
PR Newswire (US)

LLY

DewDiligence 18分前

Berobenatide—dosed monthly—appears_competitive_with_weekly Zepbound/Wegovy in efficacy/tolerability—see slide 7 at the link in #msg-177679183.

PFE

janice shell 18分前

It’s about time!!

GeorgSchreiberEU 21分前

Interesting development:

MSN has updated the name (not the ticker symbol) ... while OTC website still shows Natama

https://www.msn.com/en-us/money/stockdetails/fi-b19gfr?ocid=msedgntp&id=b19gfr

NATM

Rattlershehe 23分前

Well, 55 his to skinny. Sigma pharmaceuticals was not in our wheelhouse. As an advisor to the company, the easiest way that I could say is. The whole Sigma thing went south as soon as the books needed to be audited. They did not want anyone in their business.
Methylene blue came into the pic

KRTL

brazen22 24分前

The “as quickly as possible” versus “as many as possible” framing has a problem.

If someone had GBM 2.5 years ago, I doubt they would view delay as acceptable because it might help reach more patients later. For the current GBM population, the fastest path matters.

Appr

NWBO

mascale 25分前

Qatar (royals) famous for recent lawful outcomes.

HIRU

TightCoil 25分前

FNMA

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

COSCIENS Biopharma Inc (CSCI)

COSCIENS Biopharma Inc (CSCI) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

主要統計と詳細

CSCI 最新ニュース

COSCIENS Announces Exclusive Distribution Agreement with Wuzhou Drug International for Macrilen® in Hainan-Guangdong-Hong Kong-Macao Greater Bay Area and Singapore

COSCIENS Biopharma Inc. Announces Leadership Change

COSCIENS Biopharma Inc. Reports Third Quarter 2025 Financial Results and Provides Strategic Initiatives Update

Form 25 - Notification of the removal from listing and registration of matured, redeemed or retired securities

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

COSCIENS Announces Exclusive Distribution Agreement with Wuzhou Drug International for Macrilen® in Hainan-Guangdong-Hong Kong-Macao Greater Bay Area and Singapore

COSCIENS Biopharma Inc. Announces Leadership Change

COSCIENS Biopharma Inc. Reports Third Quarter 2025 Financial Results and Provides Strategic Initiatives Update

Form 25 - Notification of the removal from listing and registration of matured, redeemed or retired securities

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

CSCI - Frequently Asked Questions (FAQ)

CSCI 取引

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

無料で登録してください:

広告を削除する

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS